RxSight, Inc. (RXST): Capital Expenditures

Annual figures by period end, from SEC filings.

$3.83M
Year ended 2025-12-31
$4.43M
Trailing 12 months to 2026-06-30
+17.0%
3-year compound annual growth
+8.6%
5-year compound annual growth
$5.44M2020-12-31: $2.54M2021-12-31: $1.94M2022-12-31: $2.39M2023-12-31: $4.81M2024-12-31: $5.44M2025-12-31: $3.83M$3.83M
2020-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$3.83M-29.6%2026-02-25, From 2025-01-01
2024-12-31$5.44M+13.0%2026-02-25, From 2024-01-01
2023-12-31$4.81M+101.2%2026-02-25, From 2023-01-01
2022-12-31$2.39M+23.4%2025-02-25, From 2022-01-01
2021-12-31$1.94M-23.6%2023-03-06, From 2021-01-01
2020-12-31$2.54Mn/a2022-03-08, From 2020-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Ophthalmic Goods), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
RxSight, Inc. (RXST)2025-12-31$3.83M-29.6%
Staar Surgical Co (STAA)2026-01-02$5.82M-75.1%
Warby Parker Inc. (WRBY)2025-12-31$67.05M+4.7%
National Vision Holdings, Inc. (EYE)2026-01-03$72.84M-23.7%
Cooper Companies, Inc. (COO)2025-10-31$362.40M-14.0%
Bausch & Lomb Corp (BLCO)2025-12-31$349.00M+19.9%
Innovative Eyewear Inc (LUCYW)2025-12-31$72.5K+16.6%

Compare RXST, STAA, WRBY, EYE side by side · Screen every company in Ophthalmic Goods ↗